SK Bioscience
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SK Bioscience is listed on KOSPI and classified under Health Care, Pharmaceuticals. Its market value is US$2.1B. In FY2025 it reported revenue of US$491.6M and an operating loss of US$93.2M.
A written company profile is not available yet; the facts above come from exchange and DART data.
SK Bioscience in five facts
Where is SK Bioscience listed and in which sector?
SK Bioscience (Korean name: SK바이오사이언스) trades under KRX code 302440 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is SK Bioscience?
Its market capitalisation was US$2.1B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were SK Bioscience's latest annual revenue and operating profit?
For fiscal year 2025, SK Bioscience reported revenue of US$491.6M, an operating loss of US$93.2M and a net loss of US$42.4M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 143.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (consolidated) (preliminary) (fair disclosure)
SK Bioscience filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$110M (−3.8% year on year), an operating loss of US$11.1M and a net loss of US$9.94M.
Earnings · Aug 10 - Supply contract signed
SK Bioscience disclosed a supply contract, worth US$15.6M, about 3.67% of its recent annual revenue, running through Jun 2027.
Supply contract · Jun 23 - Treasury share acquisition: results reportTreasury Shares · Jun 16
- Operating results (consolidated) (preliminary) (fair disclosure)
SK Bioscience filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$117M (+9.1% year on year), an operating loss of US$30.8M and a net loss of US$25M.
Earnings · May 6 - Material event report (treasury share acquisition)
SK Bioscience disclosed a plan to buy back its own shares worth US$11.6M, about 0.6% of its market value.
Treasury Shares · Apr 28 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SK Bioscience reported consolidated results for FY2025: revenue of US$448M (+143.5% year on year), an operating loss of US$85M and a net loss of US$38.7M.
Earnings · Feb 3 - Operating results (consolidated) (preliminary) (fair disclosure)
SK Bioscience filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$127M (+17.4% year on year), an operating loss of US$35.5M and a net loss of US$38.8M.
Earnings · Feb 3